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Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and
Food Allergens (NDA) was asked to deliver an opinion on phenylcapsaicin as a novel food (NF)
pursuant to Regulation (EU) 2015/2283. Phenylcapsaicin is a chemically synthesised analogue of
capsaicin intended to be marketed in food supplements and in foods for special medical purposes to
the general population above the age of 11 years old at a maximum level of 2.5 mg/day. The highest
intake of the NF is 2.5 mg/day which corresponds to 36 lg/kg body weight (bw) per day for adults,
and 58 lg/kg bw per day for adolescents (10–14 years). The Panel considers that there is no concern
with respect to genotoxicity of the NF. The reference point derived based on a 13-week rat study was
the lowest of the model averaged BMDL20 values of 37.2 mg/kg bw per day in females for increased
plasma alanine aminotransferase (ALAT) levels. The Panel concludes that the NF, phenylcapsaicin, is
safe under the proposed uses and use levels.
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Summary
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and
Food Allergens (NDA) was asked to deliver a scientific opinion on phenylcapsaicin as a novel food (NF)
pursuant to Regulation (EU) 2015/2283. The assessment of the safety of this NF, which follows the
methodology set out in the EFSA Guidance on the preparation and presentation of an application for
authorisation of a NF1 in the context of Regulation (EU) 2015/2283 and in the Commission
Implementing Regulation (EU) 2017/2469, is based on the data supplied in the application and
information submitted by the applicant following EFSA’s requests for supplementary information and
additional data identified by the Panel.
The NF which is the subject of the application is phenylcapsaicin (> 98%), a chemically synthesised
analogue of capsaicin. The NF is intended to be marketed in food supplements and in foods for special
medical purposes to the general population above the age of 11 years old at a maximum level of
2.5 mg/day. The highest intake of the NF is 2.5 mg/day which corresponds to 36 lg/kg body weight
(bw) per day for adults (considering an average bodyweight of 70 kg) and 58 lg/kg bw per day for
adolescents (10–14 years) (considering an average bodyweight of 43.4 kg).
The information provided on composition, specifications, production process and stability of the NF
does not raise safety concerns. The Panel considers that phenylcapsaicin does not have a nutritionally
relevant role in the diet and that the consumption of the NF is not nutritionally disadvantageous.
The Panel considers that there is no concern with respect to genotoxicity of the NF. The applicant
provided a 90-day study where there were several changes related to effects in the gastrointestinal
tract and the liver. The Panel considers both the effects observed as critical effects related to the
compound. The reference point (RP) derived based on the critical effects of phenylcapsaicin lowest of
the model averaged BMDL20 values for females for increased plasma alanine aminotransferase (ALAT)
levels was 37.2 mg/kg bw per day (females).
The Panel considers that based on the proposed conditions of use, the margin of exposure between
the RP and the maximal exposure to the NF of 1,033 for adults and 643 for adolescents are sufficient.
The Panel concludes that the NF, phenylcapsaicin, is safe under the proposed uses and use levels.
1 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), Turck D, Bresson J-L, Burlingame B, Dean T,
Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle H, Naska A, Neuh€auser-Berthold M, Nowicka G,
Pentieva K, Sanz Y, Siani A, Sj€odin A, Stern M, Tome D, Vinceti M, Willatts P, Engel K-H, Marchelli R, P€oting A, Poulsen M,
Salminen S, Schlatter J, Arcella D, Gelbmann W, de Sesmaisons-Lecarre A, Verhagen H and van Loveren H, 2016. Guidance on
the preparation and presentation of an application for authorisation of a novel food in the context of Regulation (EU) 2015/2283.
EFSA Journal 2016;14(11):4594, 24 pp. https://doi.org/10.2903/j.efsa.2016.4594
Safety of phenylcapsaicin as a novel food





1.1. Background and Terms of Reference as provided by the European Commission ................................ 5





3.2. Identity of the NF......................................................................................................................... 6
3.3. Production process ....................................................................................................................... 6
3.4. Compositional data....................................................................................................................... 6
3.4.1. Stability ....................................................................................................................................... 7
3.5. Specifications ............................................................................................................................... 7
3.6. History of use of the NF and/or of its source .................................................................................. 8
3.6.1. History of use of the source .......................................................................................................... 8
3.6.2. History of use of the NF................................................................................................................ 8
3.7. Proposed uses and use levels and anticipated intake....................................................................... 8
3.7.1. Target population ......................................................................................................................... 8
3.7.2. Proposed uses and use levels ........................................................................................................ 8
3.7.3. Anticipated intake of the NF.......................................................................................................... 9
3.7.4. Combined intake from the NF and other sources ............................................................................ 9
3.7.5. Estimate of exposure to undesirable substances ............................................................................. 9
3.7.6. Precautions and restrictions of use ................................................................................................ 9
3.8. Absorption, distribution, metabolism and excretion (ADME) ............................................................. 9
3.9. Nutritional information .................................................................................................................. 10
3.10. Toxicological information............................................................................................................... 10
3.10.1. Genotoxicity................................................................................................................................. 10
3.10.2. Subchronic toxicity ....................................................................................................................... 10
3.10.3. Human studies ............................................................................................................................. 11
3.10.4. Other studies ............................................................................................................................... 11
3.11. Allergenicity ................................................................................................................................. 11
4. Discussion ................................................................................................................................... 11
5. Conclusions.................................................................................................................................. 12
Steps taken by EFSA ................................................................................................................................ 12
References............................................................................................................................................... 12
Abbreviations ........................................................................................................................................... 13
Appendix A – Comparisons of ADME/Pf properties in rats between capsaicin and phenylcapsaicin .................. 14
Appendix B – Genotoxicity studies of Phenylcapsaicin.................................................................................. 15
Appendix C – Results of oral dose 90-day study.......................................................................................... 16
Appendix D – Benchmark dose modelling report ......................................................................................... 21
Safety of phenylcapsaicin as a novel food
www.efsa.europa.eu/efsajournal 4 EFSA Journal 2019;17(6):5718
1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
On 7 February 2018, the company aXichem AB, submitted a request to the European Commission
in accordance with Article 10 of Regulation (EU) No 2015/2283 to place on the European Union (EU)
market phenylcapsaicin as a novel food.
In accordance with Article 10(3) of Regulation (EU) 2015/2283, the European Commission asks the
European Food Safety Authority to provide a scientific opinion by carrying out the assessment for
phenylcapsaicin as a novel food ingredient.
2. Data and methodologies
2.1. Data
The safety assessment of this novel food (NF) is based on data supplied in the application and
information submitted by the applicant following EFSA’s requests for supplementary information.
During the assessment, the Panel identified additional data which were not included in the
application: Paulsen et al. (2018).
Administrative and scientific requirements for NF applications referred to in Article 10 of Regulation
(EU) 2015/2283 are listed in the Commission Implementing Regulation (EU) 2017/24692.
A common and structured format on the presentation of NF applications is described in the EFSA
guidance on the preparation and presentation of a NF application.1 As indicated in this guidance, it is
the duty of the applicant to provide all of the available (proprietary, confidential and published)
scientific data, including both data in favour and not in favour to supporting the safety of the proposed
NF.
This NF application includes a request for protection of proprietary data in accordance with Article
26 of Regulation (EU) 2015/2283. Data claimed to be proprietary by the applicant include: Donath
(2016, unpublished), Feng et al. (2012a, unpublished), Feng et al. (2012b, unpublished), Schreib
(2015, unpublished), Stiller (2016, unpublished) and Yang and Dong (2015, unpublished). The
Panel considers that it could not have reached the conclusion on the safety of the NF under the
proposed conditions of use without all these studies provided by the applicant.
2.2. Methodologies
The assessment follows the methodology set out in the EFSA guidance on NF applications and the
principles described in the relevant existing guidance documents from the EFSA Scientific Committee.
The legal provisions for the assessment are laid down in Article 11 of Regulation (EU) 2015/2283 and
in Article 7 of the Commission Implementing Regulation (EU) 2017/2469.
This assessment concerns only risk that might be associated with consumption of the NF under the




The NF which is the subject of the application is phenylcapsaicin (> 98%), a chemically synthesised
analogue of capsaicinoids that occur naturally in plants of the Capsicum genus. According to article 3
of the Regulation (EU) 2015/2283, the NF falls under category (i), i.e. food with a new or intentionally
modified molecular structure, where that structure was not used as, or in, a food within the Union
before 15 May 1997. The NF is intended to be marketed in food supplements and in foods for special
medical purposes for the general population above the age of 11 years old at a maximum level of
2.5 mg/day.
2 Commission Implementing Regulation (EU) 2017/2469 of 20 December 2017 laying down administrative and scientific
requirements for applications referred to in Article 10 of Regulation (EU) 2015/2283 of the European Parliament and of the
Council on novel foods. OJ L 351, 30.12.2017, pp. 64–71.
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3.2. Identity of the NF
The NF is chemically synthesised phenylcapsaicin (> 98%). Phenylcapsaicin has a molecular weight
of 337.41 Da, solubility in water of 0.00193 g/L, a partition coefficient (n-octanol/water) of 2.34. The
pH is 6.12 at 25°C and it has a density of 1.152 g/cm3 at 20°C. The structure of phenylcapsaicin
(N-[(4-hydroxy-3-methoxyphenyl)methyl]-7-phenylhept-6-ynamide, C22H23NO3, CAS no: 848127-67-3)
is shown in Figure 1. Compared to the naturally occurring capsaicin, phenylcapsaicin presents a
phenylethynyl group on the acyl chain.
To characterise the identity of the NF, the applicant provided a series of analyses on
phenylcapsaicin including: high-performance liquid chromatography (HPLC), electrospray ionisation
mass spectrometry (ESI-MS), nuclear magnetic resonance (NMR), infrared (IR) spectroscopy and
ultraviolet (UV) spectroscopy.
3.3. Production process
The NF is produced by a two-step chemical synthesis under controlled conditions. The first step is
the production of the acetylenic acid intermediate through the reaction of phenyl acetylene with a
carboxylic acid derivative. The second step comprises several reactions of the acetylenic acid
intermediate with vanillylamine derivative to produce the final product. Phenylcapsaicin will be
formulated with cellulose, fats and/or oil prior to use to a final concentration of 1–1.5%. The applicant
provided detailed information on key parameters and critical control points of the production process.
The Panel considers that the production process is sufficiently described and does not raise safety
concerns.
3.4. Compositional data
The applicant provided results from batch-to-batch analyses of five different production lots of the
NF and the methods used for the analyses (Table 1). In these batches, the NF had a content of
phenylcapsaicin > 98%, a water content ≤ 0.2%, a total content of residual solvents < 0.6%, and a
content of process-related by-products < 1%. All investigated batches met the specifications (see
Section 3.5) regarding microbiological contaminants and heavy metals.
Figure 1: Structure of phenylcapsaicin and the structurally related capsaicin
Table 1: Batch-to-batch analyses of five batches of the NF
Parameter (unit)
Batch number
Batch 1 Batch 2 Batch 3 Batch 4 Batch 5
Assay (HPLC, %) 98.4 98.34 98.29 98.11 98.17
Moisture (%) 0.07 0.15 0.09 0.2 0.11
Total synthesis related
by-products (%)
0.58 0.47 0.44 0.53 0.65
N,N-dimethyl formamide
(mg/kg)
13 11 12 9 17
Dichloromethane (mg/kg) 19 72 26 4 8
Dimethoxyethane (mg/kg) 2 5 6 3 7
Ethyl acetate (mg/kg) 1900 1900 2002 2100 2008
Other solvents (%) 0.25 0.18 0.15 0.29 0.21
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The Panel considers that the information provided on the composition of the NF is sufficient and
does not raise safety concerns.
3.4.1. Stability
The applicant provided two studies on the stability of the NF, where five batches of the NF were
stored tightly sealed and in the dark. One study was performed under ambient conditions (25  2°C,
60  3% relative humidity) for up to 24 months, and the other under accelerated conditions
(40  2°C; 75  2% relative humidity) up to 6 months.
Upon storage under ambient conditions, there was an average decrease of phenylcapsaicin of
0.29% (0.38–0.22%) after 24 months. Storage under accelerated conditions resulted in phenylcapsaicin
decreases of 0.20% (0.31–0.08%) after 3 months and 0.36% (0.49–0.24%) after 6 months.
The Panel considered that the data provided gave sufficient information with respect to the stability
of the NF.
3.5. Specifications
The specifications of the NF as provided by the applicant are shown in Table 2.
Table 2: Product specifications for phenylcapsaicin
Parameter Specification limit Method
Purity (%) > 98 HPLC In-house method
Moisture (%) < 0.5 USP 921
Total synthesis related production by-products (%) < 1 HPLC In house method
N,N-dimethyl formamide (mg/kg) ≤ 880 USP 467
Dichloromethane (mg/kg) ≤ 600 USP 467
Dimethoxyethane (mg/kg) ≤ 100 USP 467
Ethyl acetate (mg/kg) ≤ 5,000 USP 467
Other solvents (%) ≤ 0.5 USP 467
Microbiological parameters
Total plate count (CFU/g) < 10 USP 61
Yeast and mould (CFU/g) < 10 USP 61
Coliforms (CFU/g) < 10 USP 61
Escherichia coli (Presence–Absence/10 g) Absence USP 62
Salmonella (Presence–Absence/10 g) Absence USP 62
Parameter (unit)
Batch number
Batch 1 Batch 2 Batch 3 Batch 4 Batch 5
Microbiological parameters
Total plate count (CFU/g) < 10 < 10 < 10 < 10 < 10
Yeast and mould (CFU/g) < 10 < 10 < 10 < 10 < 10
Coliforms (CFU/g) < 10 < 10 < 10 < 10 < 10
Escherichia coli (Presence–
Absence/10 g)
ND ND ND ND ND
Salmonella (Presence–Absence/
10 g)
ND ND ND ND ND
Heavy metals
Lead (mg/kg) ND ND ND ND ND
Cadmium (mg/kg) ND ND ND ND ND
Mercury (mg/kg) 0.0024 0.006 0.007 0.0038 0.0056
Arsenic (mg/kg) 0.08 0.05 0.11 0.12 0.1
HPLC: high-performance liquid chromatography; CFU: colony forming units; ND: not detected.
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The Panel considers that the information provided on the specification and the batch-to-batch
variability of the NF is sufficient and does not raise safety concerns.
3.6. History of use of the NF and/or of its source
3.6.1. History of use of the source
The NF is a novel compound produced by chemical synthesis.
3.6.2. History of use of the NF
The chemically synthesised phenylcapsaicin has no existing history of use as food in the EU.
However, capsaicinoids have a history of use causing the sharply burning taste of the fruits of many
varieties of the genus Capsicum (e.g. chillies and peppers) (BfR, 2011).
In 2002, the Scientific Committee on Food (SCF) evaluated capsaicin as a flavouring substance or in
ingredients with flavouring properties. They concluded that the data available at that time was not
sufficient to establish a safe exposure level for capsaicinoids in food. The SCF also gave a rough
estimate of the maximum daily intake of capsaicinoids from mild chillies and paprika in Europe of 1.5
mg/day (SCF, 2002).
Risks related to acute exposure to capsaicin were evaluated by the Federal Institute for Risk
Assessment (BfR) of Germany in 2011 (BfR, 2011). In their report, the BfR described observations of
undesirable effects (such as irritation of mucous membranes, nausea, vomiting and hypertension) in
individuals with excessive high consumption; however, the ingested dose of capsaicinoids was
unknown in these cases. In this assessment, it was also considered that consumption of one meal
containing capsaicin causing hotness which can be tolerated by adults would correspond to an intake
of capsaicin up to 5 mg/kg bw (BfR, 2011). The BfR also highlighted that children appeared to be
particularly sensitive.
In 2012, EFSA evaluated the safety of the related capsinoid dihydrocapsiate as a NF pursuant to
regulation EC 258/97. In that application, chemical synthesised dihydrocapsiate was intended as a NF
ingredient for incorporation into foods of various categories at concentration levels varying from 8 to
2,050 mg/kg. Dihydrocapsiate was considered safe under the proposed conditions of use, with the
97.5th percentile intake estimate of 34 mg/day for adults and elderly and calculations based on body
weights resulted in the highest intakes being 1.3 mg/kg bw per day for preschool children (EFSA NDA
Panel, 2012).
3.7. Proposed uses and use levels and anticipated intake
3.7.1. Target population
The applicant intends to market the NF to the general population above the age of 11 years.
3.7.2. Proposed uses and use levels
The applicant intends to market the NF as a food supplement and in foods for special medical
purposes at levels of 2.5 mg/day. The NF from food supplements and foods for special medical
purposes are not meant to be consumed concomitantly.
Parameter Specification limit Method
Heavy metals
Lead (mg/kg) < 1 USP 231
Cadmium (mg/kg) < 1 USP 231
Mercury (mg/kg) < 0.1 USP 231
Arsenic (mg/kg) < 1 USP 231
Lead (mg/kg) < 1 USP 231
HPLC: high-performance liquid chromatography; CFU: colony forming units; USP: United States Pharmacopeia.
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3.7.3. Anticipated intake of the NF
At the proposed uses and use levels (2.5 mg/day), the intake of the NF could be up to 36 lg/kg
bw per day for a 70-kg adult and up to 58 lg/kg bw per day for adolescents (10–14 years)
considering an average bodyweight of 43.4 kg (EFSA Scientific Committee, 2012).
3.7.4. Combined intake from the NF and other sources
Phenylcapsaicin is not naturally present in foods, and there will thus not be a combined intake from
the NF and other sources.
The Panel notes that phenylcapsaicin acts via the transient receptor potential vanilloid subfamily 1
(TRPV1) receptor as other capsaicinoids do. The intended intake of phenylcapsaicin of 2.5 mg/day
may add to the intake of capsaicinoids from foods if consumed simultaneously. The estimated
maximum daily intake of capsaicinoids from mild chillies and paprika in Europe is 1.5 mg/day (SCF,
2002). This is low compared to the 5 mg/kg bw which may be consumed by an adult with one meal
(BfR, 2011).
3.7.5. Estimate of exposure to undesirable substances
With the proposed conditions of use and specifications of the residual process-related by-products,
the Panel considers the exposure to undesirable substances does not raise safety concerns.
3.7.6. Precautions and restrictions of use
No additional precautions of use were addressed by the applicant.
3.8. Absorption, distribution, metabolism and excretion (ADME)
The applicant provided two in vivo ADME studies performed in parallel, one with phenylcapsaicin
and one with capsaicin (Feng et al., 2012a,b). The studies were neither performed according to OECD
test guideline 417 nor compliant with good laboratory practice (GLP). Male Sprague–Dawley (SD) rats
received a single oral dose of 50 mg/kg of the 14C radiolabelled test material. Bile, plasma, blood and
tissue samples were collected at 0.5, 2 and 24 h post-dosing, and urine and faeces samples were
collected up to 7 days post dosing. Radioactivity was determined in blood, plasma, liver, brain,
stomach, small intestine, kidney, spleen, lung, heart, testes, skeletal muscle and fat. Metabolites were
identified in plasma, urine and faeces. In addition, radioactivity and metabolites in bile were
determined in bile duct-cannulated rats up to 24 h after oral application (Appendix A).
Both, phenylcapsaicin and capsaicin were rapidly absorbed at similar rates reaching maximum levels
in the blood 0.5 h post-dosing. The radioactivity was distributed to various tissues, and was most
abundant in the small intestine, stomach and liver within 0.5 h post-dosing. An increase in radioactivity
was found in fat from 0.5 to 24 h post-dosing.
Numerous metabolites were identified. The dominant metabolic pathway for capsaicin was
glucuronidation, whereas it was oxygenation and glucuronidation for phenylcapsaicin. Of the labelled
14C-phenylcapsaicin and 14C-capsaicin, 72% and 47% were identified in the bile within 24 h post-oral
dose to rats, with approximately 2% and 0.4% as the intact parent compound.
The compounds were excreted through both urine and faeces with a majority occurring in the first
24 h after oral dosing. A higher amount of radioactivity was excreted in the faeces after application of
phenylcapsaicin compared to capsaicin. The recovery rates of phenylcapsaicin (54.1%) and capsaicin
(47.6%) in excreta and carcass were similar within 7 days post dosing. The lack of full recovery in
faeces, urine and carcass was attributed by the authors of the study to transfer of 14C from the
radiolabelled carbonyl group to acetyl coenzyme after cleavage of the amide bond. This could lead to
incorporation into endogenous substances, e.g. in fat or to biotransformation to 14CO2 and other
14C
labelled volatile organic compounds that are expired. Radioactivity in expired air was, however, not
measured.
Overall, the Panel notes that phenylcapsaicin derived radioactivity was rapidly absorbed, widely
distributed in various tissues, metabolised by the liver, excreted into the bile and eliminated mainly via
faeces.
Safety of phenylcapsaicin as a novel food
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3.9. Nutritional information
The Panel considers that phenylcapsaicin does not have a nutritionally relevant role in the diet and
is not nutritionally disadvantageous under the proposed conditions of use.
3.10. Toxicological information
The applicant provided a bacterial reverse mutation test, an in vitro mammalian micronucleus test
and a subchronic toxicity study. After a request from the Panel, the applicant also provided an
unpublished study (Yang and Dong, 2015) cited by Paulsen et al. (2018).
3.10.1. Genotoxicity
In a bacterial reverse mutation test compliant with OECD 471 and GLP with Salmonella
Typhimurium strains TA98, TA100, TA1535, TA1537 and TA102, with and without metabolic activation
(Schreib, 2015 unpublished; Paulsen et al., 2018), phenylcapsaicin was non-mutagenic (Appendix B).
In an in vitro mammalian cell micronucleus test with human lymphocytes compliant with OECD 487
and GLP with and without metabolic activation (Donath, 2016 unpublished; Paulsen et al., 2018),
phenylcapsaicin was not clastogenic or aneugenic (Appendix B). The Panel considers that taking into
account the results of the tests performed, there are no concerns regarding genotoxicity of the NF.
3.10.2. Subchronic toxicity
The applicant provided a subchronic 90-day repeat-dose oral toxicity study in compliance with
OECD TG 408 and GLP in which groups of Wistar rats (15/sex per group in control and high-dose
group and 10/sex per group in mid- and low-dose groups) were administered the NF by gavage at
dose levels of 0, 30, 100 or 250 mg/kg bw per day (Stiller, 2016; unpublished; Paulsen et al., 2018).
In this study, several targets systems were affected after administration of phenylcapsaicin to rats
(Appendix C). Effects were observed in the gastrointestinal tract, such as salivation and diarrhoea,
inflammation in the glandular stomach, forestomach and caecum, which can be attributed to the
irritating properties of the compound. The haematological effects (decreases in erythrocytes and
reticulocytes) may be secondary to bleeding and sustained inflammation in the gastrointestinal tract.
Reduced spleen weights, depletion of lymphocytes in spleen and lymph nodes as well as reduced
cellularity in the bone marrow point to the haematopoetic system as another target. Furthermore,
phenylcapsaicin affects the liver as can be concluded from increases in liver enzyme levels (alanine
aminotransferase (ALAT) and alkaline phosphatase (AP), increases in prothrombin time, decreased
levels of glucose, cholesterol, bilirubin and bile acids, increased liver weights and effects in
histopathological examinations, which included diffuse hepatocellular hypertrophy, periportal
vacuolation, eosinophilic cytoplasmic inclusions and focal necrosis.
Most effects were dose related, and not reversed in the recovery group or even more pronounced
(e.g. white blood cell (WBC) counts, cholesterol). In contrast, for some liver enzymes (aspartate
aminotransferase (ASAT), ALAT and AP), levels in the male recovery group were even lower than in the
controls. Male rats were generally more susceptible than female rats.
The authors of the study considered 100 mg/kg bw per day as the no observable adverse effect
level (NOAEL) for systemic toxicity based on degenerative changes in the liver and 30 mg/kg bw per
day as the NOAEL for local effects due to irritating effects in the stomach.
The Panel noted that some effects were statistically significant already at the lowest dose of 30 mg/kg
bw per day and therefore evaluated these effects. Upon request by EFSA, the applicant provided a
benchmark dose (BMD) assessment and some considerations on the evaluation of the effects. The BMD
assessment followed the EFSA Guidance on the BMD approach (EFSA Scientific Committee, 2017), using
the EFSA web-tool for BMD analysis, which is based on PROAST software (Appendix D). In addition, EFSA
performed a BMD analysis of the effects on bodyweight and the erosions and ulcers in the stomach
applying the same methodology.
A dose-dependent decrease in bodyweight was observed in rats of both sexes, with no significant
changes in the food consumption observed in the rats. This can be considered an adverse effect, and
the lowest of the model averaged BMDL05 for body weight is 77.4 mg/kg bw per day (males).
The clinical symptom ‘moving of the bedding’ was observed in both sexes, which can be interpreted
as a sign of discomfort. This finding also occurred in the same intensity in the recovery group.
Similarly, salivation was also observed in the recovery group, indicating that in addition to irritating
Safety of phenylcapsaicin as a novel food
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effects of the NF, the expectation of treatment per se likely triggers responses in the animals treated
with the test material. The effects were therefore not used for deriving a reference point.
One female rat developed at 30 mg/kg bw per day slight (grade 1) erosion/ulcer of the glandular
stomach. At higher dose levels, the number of animals affected and severity of effects increased, and
also other effects in the stomach occurred. Therefore, this finding reflects first signs of irritation in the
stomach. These effects are also relevant for humans, as for capsaicin an increase in discharge of
parietal cells, pepsin secretion and potassium exfoliation (desquamation) of stomach cells was found
after ingestion of 1.5 g capsaicin dissolved in 100 mL water, the NOAEL was 0.5 g in this study (Myers
et al., 1987). In the BMD analysis of the findings on erosions and ulcers in the stomach, the lowest of
the model averaged BMDL10 was 38.7 mg/kg bw per day (females).
For other endpoints of liver toxicity, such as hepatocellular hypertrophy and periportal vacuolation
as well as relative liver weight there was a clear dose response and the BMD analyses resulted in BMD
values with narrow BMD confidence intervals. The lower confidence limit of the benchmark dose
(BMDL) values for these data are in close agreement with each other; the lowest of the model
averaged BMDL05 values for relative liver weights is 55.0 mg/kg bw per day (females) and the lowest
of the model averaged BMDL10 values for hepatocellular hypertrophy is 56.4 mg/kg bw per day
(males). Cholesterol levels were reduced by 30% in male rats and 19% in female rats, (statistically
significant in males) at the low dose of 30 mg/kg bw per day. There was a reduction of total bilirubin
levels (20% in male rats, 22% in female rats, statistically significant in female rats). The Panel notes
that decreased bilirubin levels indicate enzyme induction in the liver and may be considered as a non-
adverse effect. At higher dose levels, there are additional effects on the liver, i.e. at 100 mg/kg bw per
day, there is an increase in liver weight, hypertrophy and vacuolation in liver cells. The increase in
prothrombin time at this dose level may also point to liver toxicity. Thus, there is a dose-related
continuum of effects in the liver. There was a statistically significant dose-related increase in plasma
ALAT levels in females at the highest dose. An increase in ALAT concentrations in the blood can be
considered an adverse effect. The benchmark response (BMR) of 20% was suggested by the EFSA
Scientific Committee et al. (2017) for liver enzymes. The lowest of the model averaged BMDL20 values
for ALAT was 37.2 mg/kg bw per day (Females), and was used as the reference point (RP) for the NF.
3.10.3. Human studies
No human studies were available assessing the safety of the NF.
3.10.4. Other studies
Contact of the skin or the mucous membranes with capsaicin causes a sensation of heat, burning
and hyperaemia. This effect is mediated by binding to ‘transient receptor potential vanilloid subfamily
1’ (TRPV1) in specific nerve fibres (C-fibres) that transport calcium into the cells and subsequent
release of various mediators, e.g. Substance P.
To investigate, whether phenylcapsaicin acts similarly as capsaicin, an in vitro study was performed
by the applicant (Yang and Dong, 2015) and provided upon request from EFSA. In this study, the
uptake of fluorescent calcium via the TRPV1 channel was investigated in HEK293 cells stably
expressing the human TRPV1 channel. The EC50 (half maximal effective concentration) of
phenylcapsaicin for stimulating Ca uptake was 57.8 nM, while for capsaicin it was 26.4 nM, indicating
that phenylcapsaicin was about half as active as capsaicin.
The Panel notes that this study indicates that phenylcapsaicin acts as a capsaicin analogue.
3.11. Allergenicity
The Panel considers that the NF is a well-defined mixture with a high content of phenylcapsaicin
> 98% produced from non-protein chemical sources and that it is not expected to have allergenic
potential.
4. Discussion
The NF which is the subject of the application is phenylcapsaicin (> 98%) a chemically synthesised
analogue of capsaicin. The highest intake of the NF is 2.5 mg/day which corresponds to 36 lg/kg bw
per day for adults (considering an average bodyweight of 70 kg) and 58 lg/kg bw per day for
adolescents (10–14 years) (considering an average bodyweight of 43.4 kg).
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The information provided on composition, specifications, production process and stability of the NF
does not raise safety concerns. The Panel considers that phenylcapsaicin does not have a nutritionally
relevant role in the diet and that the consumption of the NF is not nutritionally disadvantageous under
the proposed conditions of use.
The Panel considers that there is no concern with respect to genotoxicity of the NF. The applicant
provided a 90-day study where there were several changes related to effects in the gastrointestinal
tract and the liver. The Panel considers both the effects observed as critical effects related to the
compound. The RP derived based on the critical effects of phenylcapsaicin lowest of the model
averaged BMDL20 values for the increase in plasma ALAT levels was 37.2 mg/kg bw per day (females).
The Panel considers that based on the proposed conditions of use, the margin of exposure between
the RP and the maximal exposure to the NF of 1,033 for adults and 643 for adolescents are sufficient.
5. Conclusions
The Panel concludes that the NF is safe under the proposed uses and use levels.
The Panel could not have reached the conclusion on the safety of the NF under the proposed
conditions of use without the data claimed as proprietary by the applicant, Donath (2016,
unpublished), Feng et al. (2012a, unpublished), Feng et al. (2012b, unpublished), Schreib (2015,
unpublished), Stiller (2016, unpublished) and Yang and Dong (2015, unpublished).
Steps taken by EFSA
1) Letter from the European Commission to the European Food Safety Authority with the
request for a scientific opinion on the safety of phenylcapsaicin. Ref. Ares(2018)4394500,
dated 27/08/2018.
2) On 28 August 2018, EFSA received a valid application from the European Commission on
phenylcapsaicin as NF, which was submitted by aXichem AB, and the scientific evaluation
procedure started.
3) On 20 November 2018, 7 February 2019 and 11 February 2019 EFSA requested the applicant
to provide additional information to accompany the application and the scientific evaluation
was suspended.
4) On 29 January 2019 and twice on 11 February 2019 additional information was provided by
the applicant and the scientific evaluation was restarted.
5) During its meeting on 15 05 2019, the NDA Panel, having evaluated the data, adopted a scientific
opinion on the safety of phenylcapsaicin as a NF pursuant to Regulation (EU) 2015/2283.
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BfR German Federal Institute for Risk Assessment
BMD benchmark dose
BMDL lower confidence limit of the benchmark dose
BMDU upper confidence limit of the benchmark dose
BMR benchmark response
bw body weight
CAS Chemical Abstracts Service
CFU colony forming units
EC50 half maximal effective concentration
ESI-MS electrospray ionisation mass spectrometry
GLP good laboratory practice
HPLC high-performance liquid chromatography
IR infrared
NOAEL no observable adverse effect level
NF novel food
NMR nuclear magnetic resonance
OECD Organisation for Economic Co-operation and Development
RP Reference point
TRPV1 transient receptor potential vanilloid subfamily 1
USP United States Pharmacopeia
UV ultraviolet
WBC white blood cell count
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Appendix A – Comparisons of ADME properties in rats between capsaicin and phenylcapsaicin
Table A.1: Results of ADME in rats of capsaicin and phenylcapsaicin modified from Feng et al. (2012a,b)
Capsaicin Phenylcapsaicin
Dose level 50 mg/kg including 100 p,Ci/kg 50 mg/kg including 100 p,Ci/kg
Cumulative radioactive dose in urine
within 7 days (%)
15.26 3.25
Cumulative radioactive dose in faeces
within 7 days (%)
32.26 50.86
Recovery in urine and faeces within 7
days
47.61 54.11
Radioactivity in carcass after 7 days No data 4.2%
Cumulative radioactive dose in bile
(%) within 24 h
47.06 72.29
Percent parent in bile of the dose (%)
within 4 h
1.99 0.36
Tmax in tissues and blood, plasma 0.5 h 0.5 h
Tissues with highest radioactivity after







Total number of metabolites 50 27
Metabolic pathway Hydrolysis, deamination, hydrogenation, dehydrogenation,
oxygenation, conjugation with glutathione, demethylation,
glucuronidation and sulfation
Hydrolysis, deamination, dehydrogenation, glucuronidation,
oxygenation, conjugation with glutathione, demethylation and
sulfation
Major metabolic pathway and
metabolites
M42 (31.8% of the radioactive
dose in bile), glucuronidation
M18 (61.97% of the radioactive
dose in bile), oxygenation and
glucuronidation
Blood to plasma ratio (0.5–24 h) 0.61–1.17 0.55–0.88
ADME: absorption, distribution, metabolism and excretion.
Note: Tissues collected: liver, brain, stomach, small intestine, kidney, spleen, lung, heart, testes, skeletal muscle and fat.
*: Only piece of liver was cut and used as a sample.
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Appendix B – Genotoxicity studies of Phenylcapsaicin
Table B1: Results of Schreib (2015) unpublished full study report and Donath (2016) unpublished full study report
Study Bacterial reverse mutation test assay In vitro mammalian Cell micronucleus assay
Title of the study
report
Schreib (2015), unpublished full study report (confidential)
Paulsen et al. (2018), published report
Donath, 2016;. unpublished full study report (confidential)
Paulsen et al., 2018 published report
Method OECD 471 OECD 487
Tested system Salmonella Typhimurium strains TA98, TA100, TA102, TA1535 and TA1537 Human lymphocytes
Test material NF Batch: 20141201 (98.8% phenylcapsaicin) NF Batch: 20141201 (98.8% phenylcapsaicin)
Dose/
concentration
Two independent experiments (plate incorporation (experiment 1) and
pre-incubation test (experiment 2)).
Eight concentrations of phenylcapsaicin were used for each bacterial strain
in triplicate with and without the presence of metabolic activation system
(S9 mix).
3.16, 10.0, 31.6, 100, 316, 1,000, 2,500 and 5,000 lg/plate
Dose selected based on the results of the cytotoxicity measurements and
the precipitation study of the substance.
Short-term exposure (incubated for 4 h)
 With metabolic activation (S9 mix) at concentrations 50, 100, 130 and
140 lg/mL
 Without metabolic activation (S9 mix) at concentrations of 50,100,
120 and 130 lg/mL
Long-term exposure (exposed to the NF for 44 h)




No increases in revertant colony numbers of any of the strains tested
occurred in the presence or absence of metabolic activation in both
experiments.
There was precipitation of the test item in all strains at a concentration of
5,000 lg/plate. Toxicity was observed at concentrations of 316 lg/plate
and above in the absence of S9. In the presence of S9 at 1,000 lg/plate
and above, toxicity was observed in the preincubation test with S9, and
2,500 lg/plate and above in the plate incorporation test
There was no statistically significant enhancement of micronucleated cells
observed in the experiments. Phenylcapsaicin was not clastogenic or
aneugenic in the in vitro mammalian cell micronucleus test. Cytostasis was
close to the limit of 55  5% in all experiments, 58, 57 and 60% at
highest dose tested
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Appendix C – Results of oral dose 90-day study
Table C.1: Summary of the 90-day study by Stiller (2016) and the significant findings in the study
Title of the study report 90-day repeated-dose oral toxicity study in Wistar rats with phenylcapsaicin including a 28-day recovery period (Stiller,
2016)
Tested system Groups of 6-week-old adult Wistar rats
Test material The NF Batch: 20141201 (98.8% phenylcapsaicin)
Dose/concentration (route of
administration)
The NF (suspended in polyethylene glycol 400) was prepared daily and administered to the rats by oral gavage at doses
levels of:
Control (15 animals/sex): 0 (vehicle-only)
Low dose (10 animals/sex): 30 mg/kg bw per day
Mid dose (10 animals/sex): 100 mg/kg bw per day
High dose (10 animals/sex): 250 mg/kg bw per day
Statistical analysis Results of the body weight, food consumption, parameters of haematology, blood coagulation and clinical biochemistry and
absolute and relative organ weights were analysed using one-way ANOVA and a post hoc Dunnett’s test
















0 mg/kg bw per
day + Recovery
High dose
250 mg/kg bw per
day + Recovery
Clinical observations
Animals with signs of toxicity (frequency) M 55.7 117.3 165.9** 203.5** NA 198.2**
F 55.1 103.5 164.7** 205.1** NA 191.2**
Diarrhoea (frequency) M 55.2 60.7 57.9 67.3** NA 65.4**
F 55.1 52.5 54.6 62.0** NA 66.6**
Salivation (frequency) M 0 4.8 42.3** 59.9** NA 60.0**
F 0.0 6.1 45.1** 58.2** NA 58.6**
Piloerection (frequency) M 0 0 0 0.9 NA 0.4**
F 0.0 0.0 0.1 3.5 NA 0.0
Musculoskeletal system wasp waist (frequency) M 0 0 0 0 NA 0.4**
F 0.0 0.0 0.1 1.6 NA 0.0
Spontaneous Activity
Reduced (frequency)
M 0 0 0 3.9** NA 4.0**
F 0.0 0.0 0.1 2.5** NA 4.0**
Moving the bedding (frequency) M 0 51.8 65.7** 68.9** NA 68.0**
F 0 44.8* 64.4** 68.0** NA 62.0*
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0 mg/kg bw per
day + Recovery
High dose
250 mg/kg bw per
day + Recovery
Bodyweight
Day 91 (g) M 356.53 351.30 347.60 322.80 – 329.80
F 209.33 206.22 205.44 194.56 – 210.50
Day 119 (g) M – – – – 379,00 366.25
F – – – – 210,00 207.25
Haematology
RBC (1012/L) M 9.15 9.14 8.86 8.72* 9.27 8.71
F 8.26 8.00 8.08 7.58 7.99 7.83
WBC (109/L) M 4.23 4.80 3.40 3.69 4.81 2.90*
F 3.34 2.90 2.17 3.64 2.05 1.38
MCV (fL) M 52.36 52.35 52.73 54.03* 52.22 54.45
F 55.08 53.49 54.39 54.94 54.82 55.33
Monocytes (%) M 2.35 1.89 2.75 2.22 3.44 1.53
F 2.08 1.89 2.57 3.79* 2.52 2.80
Reticulocytes (%) M 1.99 1.70 1.46 1.07** 1.35 1.70*
F 2.57 2.37 1.88 1.60 1.58 1.34
Prothrombin Time (seconds) M 22.30 23.68 25.76** 24.75* 22.92 23.43
F 24.09 25.80 25.74 24.83 23.88 25.83*
Clinical biochemistry
Total bilirubin (lmol/L) M 2.21 1.77 1.39** 1.78 2.32 1.13**
F 2.64 2.07* 1.99* 2.11 2.36 1.90
Total bile acids (lmol/L) M 69.52 45.49 34.59* 34.13* 48.55 25.58
F 66.06 54.36 55.41 67.15 39.78 31.90
Total cholesterol (mmol/L) M 1.74 1.25* 1.02** 1.08* 1.66 0.65***
F 1.27 1.03 1.08 1.33 1.08 1.32
Glucose (mmol/L) M 7.32 6.66 4.77* 4.53* 11.93 5.16**
F 5.22 4.85 4.50 6.48 6.71 7.30
Alanine aminotransferase (U/L) M 35.54 31.23 32.58 44.59 39.30 15.48***
F 34.58 26.48 35.90 59.83* 25.84 38.03
Aspartate aminotransferase (U/L) M 106.80 88.50 91.62 91.60 90.80 29.63**
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0 mg/kg bw per
day + Recovery
High dose
250 mg/kg bw per
day + Recovery
F 86.93 79.90 85.34 101.85 59.30 85.13
Alkaline phosphatase (U/L) M 103.15 112.62 113.50 123.31 115.31 33.10**
F 54.68 72.13 74.84 100.48* 57.27 67.46
Urea (mmol/L) M 9.06 9.49 9.38 9.58 5.26 2.23***
F 10.23 10.01 9.82 9.58 5.26 4.75
Sodium (mmol/L) M 131.00 125.50 121.20 125.70 125.60 57.67**
F 128.70 133.44 130.44 141.38 97.00 113.75
Potassium (mmol/L) M 4.13 3.71 3.71 3.89 3.78 1.60***
F 3.91 3.55 3.43 4.11 2.45 2.97
Organ weights
Liver (mean weight (g)) M 8.5285 8.7392 8.8405 11.3357**** 9.3246 9.2301
F 5.3444 5.4581 5.9997 7.2987**** 5.5875 6.0377
Liver weight (relative to body weight %) M 2.4232 2.4856 2.5398 3.5107 2.5543 2.8617
F 2.6058 2.6478 2.9255 3.7866 2.5819 2.8658
Spleen (mean weight (g)) M 0.7841 0.7419 0.6560 0.6200**** 0.6453 0.7266
F 0.5240 0.5003 0.5230 0.4525**** 0.5042 0.4993
Histopathology
Liver
Hepatocellular hypertrophy, diffuse (incidence/mean
severity)
M 0 0 3/1.0 9/1.0 0 0
F 0 0 0 7/1.0 0 0
Vacuolation (fatty change), periportal (incidence/mean
severity)
M 0 0 1/1.0 4/1.5 0 0
F 2/1.0 1/1.0 0 3/1.7 1/1.0 1/1.0
Eosinophilic cytoplasmic inclusions, periportal
hepatocytes (incidence/mean severity)
M 0 0 0 1/1.0 0 0
F 0 0 0 0 0 0
Focal necrosis (incidence/mean severity) M 0 0 0 0 0 0
F 0 0 0 1/1.0 0 0
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0 mg/kg bw per
day + Recovery
High dose




Hyperkeratosis, diffuse (incidence/mean severity) M 0 0 0 10/1.5 0 0
F 0 0 0 8/1.3 0 0
Squamous hyperplasia (incidence/mean severity) M 0 0 0 10/1.0 0 0
F 0 0 0 8/1.0 0 0
Oedema, submucosa (incidence/mean severity) M 0 0 0 3/2.0 0 0
F 0 0 0 3/1.0 0 0
Inflammation, submucosa (incidence/mean severity) M 0 0 0 0 0 0
F 0 0 0 1/1.0 0 0
Glandular stomach
Erosion/Ulcer (incidence/mean severity) M 0 0 1/1.0 3/1.7 0 1/1.0
F 0 1/1.0 1/2.0 5/2.4 0 1/1.0
Inflammation (incidence/mean severity) M 0 0 1/1.0 3/1.7 0 1/1.0
F 0 0 2/1.0 7/1.6 0 0
Cecum
Congestion, lamina propria (incidence/mean severity) M 0 0 2/1.0 8/1.0 0 0
F 0 0 0 2/1.0 0 0
Increased basophilia, surface epithelial cells
(incidence/mean severity)
M 0 0 3/1.0 9/1.0 0 0
F 0 0 0 5/1.0 0 0
Increased apoptosis, surface epithelial cells (incidence/
mean severity)
M 0 0 0 2/1.0 0 0
F 0 0 0 0 0 0
Others
Bone marrow (sternum) – decreased cellularity
(decreased cell density) (incidence/mean severity)
M 0 0 0 5/2.0 0 1/1.0
F 0 0 0 6/1.8 0 1/1.0
Spleen – lymphoid depletion (incidence/mean severity) M 0 0 NE 0 NE NE
F 0 0 0 1/1.0 0 0
Thymus – atrophy (incidence/mean severity) M 9/1.2 10/1.3 9/1.2 10/1.7 5/1.2 5/1.0
F 10/1.3 9/1.4 9.1.4 8/2.3 5/1.4 4/1.5
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0 mg/kg bw per
day + Recovery
High dose
250 mg/kg bw per
day + Recovery
Lymph node – axillary – lymphoid depletion (incidence/
mean severity)
M 0 NE NE 0 NE NE
F 0 0 0 1/1.0 0 0
Lymph node – mesenteric – lymphoid depletion
(incidence/mean severity)
M 0 NE NE 0 NE NE
F 0 0 0 1/1.0 0 0
Adrenal glands – cortical hypertrophy, diffuse
(incidence/mean severity)
M 0 0 0 2/1.1 0 0
F 0 0 0 5/1.0 0 0
bw: body weight; ANOVA: analysis of variance; RBC: red blood cell; WBC: white blood cell; MCV: mean corpuscular volume; C: control group; F: female; HD: high-dose group; LD: low-dose group;
M: male; MD: mid-dose group; NA: not applicable; NE: not examined, U: enzyme activity.
Values for the HD recovery group are compared to values for the C recovery group, when such data are available. otherwise, values are compared to values for the C group.
*: significantly different from control (p < 0.05).
**: significantly different from control (p < 0.01).
***: significantly different from control (p < 0.001).
****: significantly different from control (p = not reported).
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Appendix D – Benchmark dose modelling reports
Benchmark dose modelling of continuous data
Data Description
The endpoint analysed was plasma alanine aminotransferase levels, summary data for the endpoint
is found in Table D.1. The BMD analysis was performed using individual data, and therefore slightly
different results may be obtained using the summary data in the analysis.
Table D.1: Summary data of Alanine aminotransferase (Stiller, 2016)
Dose ALAT (U/L) SD n Sex
C 34.58 10.99 10 F
LD 26.48 8.32 8 F
MD 35.90 10.63 9 F
HD 59.83 35.89 8 F
C 35.54 8.88 10 M
LD 31.23 9.07 10 M
MD 32.58 7.27 10 M
HD 44.59 19.78 10 M
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Software used
Results are obtained using the EFSA web-tool for BMD analysis, which uses the R-package PROAST,
version 66.35, for the underlying calculations.
Selection of the BMR
The benchmark response (BMR) used is a 20% change in mean response compared to the
controls. The benchmark dose (BMD) is the dose corresponding with the BMR of interest.
A 90% confidence interval around the BMD will be estimated; the lower bound is reported by BMDL
and the upper bound by BMDU.
Results
Fitted Models
Table D.3: List of fitted BMD models
Model Converged Loglik npar AIC
full model Yes 32.32 9 82.64
full-v Yes 31.43 10 82.86
null model Yes 41.22 2 86.44
null model-a Yes 41.20 3 88.40
Expon. m3- Yes 35.58 4 79.16
Expon. m3-a Yes 35.54 5 81.08
Expon. m3-b Yes 34.42 5 78.84
Expon. m3-ab Yes 34.16 6 80.32
Expon. m5- Yes 35.50 5 81.00
Expon. m5-a Yes 35.46 6 82.92
Expon. m5-b Yes 34.33 6 80.66
Expon. m5-ab Yes 33.86 7 81.72
Hill m3- Yes 35.58 4 79.16
Hill m3-a Yes 35.54 5 81.08
Hill m3-b Yes 34.42 5 78.84
Hill m3-ab Yes 34.16 6 80.32
Hill m5- Yes 35.50 5 81.00
Hill m5-a Yes 35.47 6 82.94
Hill m5-b Yes 34.33 6 80.66
Hill m5-ab Yes 33.86 7 81.72
Inv.Expon. m3- Yes 35.53 4 79.06
Inv.Expon. m3-a Yes 35.49 5 80.98
Inv.Expon. m3-b Yes 34.35 5 78.70
Inv.Expon. m3-ab Yes 34.03 6 80.06
Inv.Expon. m5- Yes 35.49 5 80.98
Inv.Expon. m5-a Yes 35.46 6 82.92
Inv.Expon. m5-b Yes 34.31 6 80.62
Inv.Expon. m5-ab Yes 33.84 7 81.68
LN m3- Yes 35.55 4 79.10
LN m3-a Yes 35.51 5 81.02
LN m3-b Yes 34.38 5 78.76
LN m3-ab Yes 34.09 6 80.18
LN m5- Yes 35.49 5 80.98
LN m5-a Yes 35.46 6 82.92
LN m5-b Yes 34.31 6 80.62
LN m5-ab Yes 33.84 7 81.68
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Estimated Model Parameters
Weights for Model Averaging
Final BMD Values
Confidence intervals for the BMD are based on 200 bootstrap data sets.
Table D.4: Estimated model parameters for the BMD models
EXP HILL INVEXP LOGN
Estimate for var- 0.1466 0.1466 0.1463 0.1465
Estimate for a- 30.67 30.66 30.62 30.64
Estimate for CED-F 149.7 149.5 136.2 141.8
Estimate for CED-M 210.9 210.8 206.4 208.2
Estimate for d- 2.112 2.115 0.3659 0.6916
Table D.5: Weights for the models used in the BMD model averaging
EXP HILL INVEXP LOGN
0.24 0.24 0.26 0.25
Table D.6: Final BMD values for plasma alanine aminotransferase (ALAT) levels
Endpoint Subgroup BMDL BMDU
ALAT F 37.2 235
ALAT M 86.6 593
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Visualisation
Figure D.1: Visualisation of the individual BMD model curves
Figure D.2: Visualisation of bootstrap curves based on BMD model averaging
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